%0 Journal Article
%A Salvador Martín, Sara
%A Kaczmarczyk, Bartosz
%A Alvarez, Rebeca
%A Navas López, Víctor Manuel
%A Gallego Fernández, Carmen
%A Moreno Álvarez, Ana
%A Solar Boga, Alfonso
%A Sánchez Sánchez, César
%A Tolin, Mar
%A Velasco, Marta
%A Muñoz Codoceo, Rosana
%A Rodriguez Martinez, Alejandro
%A Vayo, Concepción A.
%A Bossacoma, Ferrán
%A Pujol Muncunill, Gemma
%A Fobelo, María J.
%A Millán Jiménez, Antonio
%A Magallares, Lorena
%A Martínez Ojinaga, Eva
%A Loverdos, Inés
%A Eizaguirre, Francisco J.
%A Blanca García, José A.
%A Clemente, Susana
%A García Romero, Ruth
%A Merino Bohórquez, Vicente
%A González de Caldas, Rafael
%A Vázquez, Enrique
%A Dopazo, Ana
%A Sanjurjo Sáez, María
%A López Fernández, Luis Andrés
%T Whole Transcription Profile of Responders to Anti-TNF Drugs in Pediatric Inflammatory Bowel Disease.
%D 2021
%@ 1999-4923
%U https://hdl.handle.net/20.500.14352/7427
%X Background: Up to 30% of patients with pediatric inflammatory bowel disease (IBD) do not respond to anti-Tumor Necrosis Factor (anti-TNF) therapy. The aim of this study was to identify pharmacogenomic markers that predict early response to anti-TNF drugs in pediatric patients with IBD. Methods: An observational, longitudinal, prospective cohort study was conducted. The study population comprised 38 patients with IBD aged < 18 years who started treatment with infliximab or adalimumab (29 responders and nine non-responders). Whole gene expression profiles from total RNA isolated from whole blood samples of six responders and six non-responders taken before administration of the biologic and after two weeks of therapy were analyzed using next-generation RNA sequencing. The expression of six selected genes was measured for purposes of validation in all of the 38 patients recruited using qPCR. Results: Genes were differentially expressed in non-responders and responders (32 before initiation of treatment and 44 after two weeks, Log2FC (Fold change) >0.6 or <−0.6 and p value < 0.05). After validation, FCGR1A, FCGR1B, and GBP1 were overexpressed in non-responders two weeks after initiation of anti-TNF treatment (Log2FC 1.05, 1.21, and 1.08, respectively, p value < 0.05). Conclusion: Expression of the FCGR1A, FCGR1B, and GBP1 genes is a pharmacogenomic biomarker of early response to anti-TNF agents in pediatric IBD.
%~